Copyright
©The Author(s) 2020.
World J Clin Cases. Nov 6, 2020; 8(21): 5116-5127
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5116
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5116
Table 1 Clinical characteristics of the patients with normal size ovarian cancer syndrome and papillary serous ovarian carcinoma, n (%)
Characteristic, patients with data available | NOCS | PSOC | P value |
Age in yr | 53.76 (110) | 52.61(152) | 0.400 |
Menopausal status | 0.579 | ||
Premenopausal | 39 (35.4) | 59 (38.8) | |
Postmenopausal | 71 (64.6) | 93 (61.2) | |
Initial symptoms | 0.003 | ||
Abdominal distension | 70 (63.6) | 63 (41.4) | |
Abdominal pain | 20 (18.2) | 26 (17.1) | |
Mass | 5 (4.5) | 54 (35.5) | |
Other | 15 (15.6) | 9 (5.9) | |
CA125 in U/mL | 1318.04 | 1863.38 | 0.039 |
CA199 in U/mL | 51.41 | 28.52 | 0.202 |
Ascites cytology | 0.057 | ||
Positive | 47 (88.6) | 34 (73.9) | |
Negative | 6 (11.3) | 12 (26.1) | |
Ascites in mL | 1658.63 | 2302.24 | 0.025 |
Misdiagnosis rate | 23.6% | 1.32% | 0.000 |
Survival rates | 0.179 | ||
1-year | 75.5% | 64.5% | |
3-year | 27.7% | 23.0% | |
5-year | 13.8% | 9.9% |
Table 2 Clinical characteristics of the patients with normal size ovarian cancer syndrome in four histological subtypes
Characteristic | Primary adnexal | MPM | EPSPC | Metastatic |
n (%) | 80 (72.7) | 2 (1.8) | 19 (17.3) | 9 (8.2) |
Age in yr | 53.28 (24-67) | 51.50 (45-58) | 56.42 (44-72) | 53.00 (35-66) |
Menopausal status | ||||
Premenopausal | 13 | 0 | 1 | 2 |
Postmenopausal | 67 | 2 | 18 | 7 |
Initial symptoms | ||||
Abdominal distension | 52 | 2 | 12 | 4 |
Abdominal pain | 14 | 0 | 5 | 1 |
Mass | 3 | 0 | 1 | 1 |
Other | 11 | 0 | 1 | 3 |
CA125 in U/mL | 1465.40 | 36.81 | 1308.14 | 205.40 |
CA199 in U/mL | 22.61 | 13.2 | 83.87 | 244.63 |
Ascites cytology | 62 | 1 | 14 | 6 |
Positive, n (%) | 37 (59.7) | 1 (100) | 8 (57.1) | 4 (66.7) |
Negative, n (%) | 25 (40.3) | 0 (0) | 6 (42.9) | 2 (33.3) |
Ascites in mL | 1717.87 | 1000 | 1500 | 1480 |
Stage, n (%) | ||||
III | 58 (72.5) | 2 (100) | 12 (63.2) | 6 (66.7) |
IV | 22 (27.5) | 0 (0) | 7 (36.8) | 3 (33.3) |
Survival rates | ||||
1-year | 79.5% | 100% | 64.7% | 66.7% |
3-year | 32.1% | 100% | 23.5% | 33.3% |
5-year | 20.5% | 50% | 5.9% | 22.2% |
Table 3 Treatment characteristics of primary normal size ovarian cancer syndrome and papillary serous ovarian carcinoma, n (%)
Characteristic, patients with data available | NOCS | PSOC | P value |
Initial surgery | 0.892 | ||
Complete | 79 (71.8) | 108 (71.1) | |
Incomplete | 31 (28.2) | 44 (28.9) | |
Operation method | 0.000 | ||
Laparotomy | 49 (44.5) | 112 (73.7) | |
Laparoscopy | 61 (55.5) | 40 (26.3) | |
Residual tumor | 0.136 | ||
Yes | 67 (60.9) | 106 (69.7) | |
No | 43 (39.1) | 46 (30.3) | |
Chemotherapy | 0.000 | ||
Platinum-based | 86 (77.3) | 142 (93.4) | |
Nonplatinum-based | 3 (2.7) | 0 (0.0) | |
Without | 22 (20) | 10 (6.6) | |
Chemotherapy numbers | 0.051 | ||
≥ 6 | 58 (65.2) | 74 (52.1) | |
< 6 | 31 (34.8) | 68 (47.9) |
Table 4 The Cox regression models for normal size ovarian cancer syndrome-specific survival prognostic factors in the univariate analysis
Factors | Overall survival | Progression-free survival | ||||
Hazard ratio | 95%CI | P value | Hazard ratio | 95%CI | P value | |
Age ≥ 50 yr | 1.314 | 0.594-2.906 | 0.500 | 0.736 | 0.290-1.871 | 0.520 |
CA125 ≥ 100 in U/mL | 3.751 | 0.898-15.664 | 0.070 | 1.163 | 0.333-4.058 | 0.813 |
CA199 ≥ 35 in U/mL | 2.546 | 1.156-5.608 | 0.020 | 1.778 | 0.483-6.543 | 0.387 |
Ascites ≥ 1000 in mL | 1.954 | 0.987-3.870 | 0.055 | 1.248 | 0.567-2.747 | 0.582 |
Stage III vs IV | 1.517 | 0.688-3.347 | 0.302 | 0.617 | 0.238-1.603 | 0.322 |
Residual tumor | 2.348 | 0.969-5.691 | 0.059 | 1.059 | 0.431-2.599 | 0.901 |
Complete surgery | 1.632 | 0.948-3. 061 | 0.512 | 0.842 | 0.267-2.134 | 0.534 |
Differentiation | 0.047 | 0.000-42.817 | 0.512 | 0 | 0 | 0 |
Histological subtype | 1.023 | 0.818-2.342 | 0.342 | 0.736 | 0.278-1.899 | 0.365 |
Operation method | 0.541 | 0.268-1.091 | 0.086 | 1.114 | 0.512-2.424 | 0.785 |
Platinum-based CT | 0.355 | 0.083-1.522 | 0.163 | 0.682 | 0.085-5.474 | 0.719 |
Chemotherapy numbers ≥ 6 | 0.307 | 0.138-0.684 | 0.004 | 0.384 | 0.117-1.261 | 0.115 |
Table 5 The Cox regression models for normal size ovarian cancer syndrome-specific survival in the multivariate analysis
Factors | Overall survival | ||
HR | 95%CI | P value | |
CA125 ≥ 100 in U/mL | 0.785 | 0.093-6.589 | 0.823 |
CA199 ≥ 35 in U/mL | 3.004 | 1.133-7.960 | 0.027 |
Ascites ≥ 1000 in mL | 1.935 | 0.814-4.599 | 0.135 |
Residual tumor | 1.417 | 0.492-4.078 | 0.518 |
Chemotherapy numbers ≥ 6 | 0.313 | 0.127-0.770 | 0.012 |
Histological subtype | 1.124 | 0.744-3.451 | 0.235 |
Stage | 0.769 | 0.642-3.477 | 0.176 |
Operation method | 1.213 | 0.984-3.461 | 0.115 |
- Citation: Yu N, Li X, Yang B, Chen J, Wu MF, Wei JC, Li KZ. Clinical characteristics and survival of patients with normal-sized ovarian carcinoma syndrome: Retrospective analysis of a single institution 10-year experiment. World J Clin Cases 2020; 8(21): 5116-5127
- URL: https://www.wjgnet.com/2307-8960/full/v8/i21/5116.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i21.5116